Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels
Niki F. Brisnovali, Isabelle Franco, Amira Abdelgawwad, Hio Lam Phoebe TsouiD, Thong Huy CaoiD, John E. McDonaldiD, Antonio RivaiD, Guy A. RutteriD, Elina AkalestouiD
Abstract
Despite recent therapeutic advances, achieving optimal glycaemic control remains a challenge in managing Type 2 Diabetes (T2D). Sodium-glucose co-transporter type 2 (SGLT2) inhibitors have emerged as effective treatments by promoting urinary glucose excretion. However, the full scope of their mechanisms extends beyond glycaemic control. At present, their immunometabolic effects remain elusive. To investigate the effects of SGLT2 inhibition or deletion, we compared the metabolic and immune phenotype between high fat diet-fed control, chronically dapagliflozin-treated mice and total-body SGLT2/Slc5a2 knockout mice. SGLT2 null mice exhibited superior glucose tolerance and insulin sensitivity compared to control or dapagliflozin-treated mice, independent of glycosuria and body weight. Moreover, SGLT2 null mice demonstrated physiological regulation of corticosterone secretion, with lowered morning levels compared to control mice. Systemic cytokine profiling also unveiled significant alterations in inflammatory mediators, particularly interleukin 6 (IL-6). Furthermore, unbiased proteomic analysis demonstrated downregulation of acute-phase proteins and upregulation of glutathione-related proteins, suggesting a role in the modulation of antioxidant responses. Conversely, IL-6 increased SGLT2 expression in kidney HK2 cells suggesting a role for cytokines in the effects of hyperglycemia. Collectively, our study elucidates a potential interplay between SGLT2 activity, immune modulation, and metabolic homeostasis. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC="FIGDIR/small/590099v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@140041forg.highwire.dtl.DTLVardef@1ceb1b7org.highwire.dtl.DTLVardef@f575b1org.highwire.dtl.DTLVardef@101d5b4_HPS_FORMAT_FIGEXP M_FIG C_FIG Article HighlightsO_LIThe role of Sodium-glucose co-transporter type 2 (SGLT2) in immunity regulation remains elusive, despite extensive research in SGLT2 inhibitors. C_LIO_LIWe sought to discern the effects of SGLT2 inhibition or deletion on metabolic and immune profiles in high-fat-fed mice, focussing on corticosterone regulation and cytokine alterations. C_LIO_LISGLT2 null mice exhibit enhanced insulin sensitivity, alongside physiologically regulated corticosterone levels and significant alterations in inflammatory cytokines, and we identified changes in protein expression suggestive of antioxidant modulation. C_LIO_LIOur findings emphasize the interplay between immune responses and metabolic regulation mediated by SGLT2 activity. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.53
- Field percentile
- top 40%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Kidney single-cell transcriptomes uncover SGLT2i-induced metabolic reprogramming via restoring glycolysis and fatty acid oxidation
Ying Shi, Vivek Bhalla·bioRxiv·Oct 31, 2023
- Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis
Yinghan Zhu, Yiting Wang, … Xiaojun Liu·Acta Biochimica et Biophysica SinicaPeer-reviewed·Sep 15, 2026
- Metabolic Reprogramming Coordinates Mannose and Glutamine Metabolism to Maintain Glucose Homeostasis During Glycosuria
Nadia Rashid, Moses Temitayo Otunla, … Kavaljit H. Chhabra·bioRxiv·May 22, 2026
- Sodium-glucose co-transporter 2 Inhibitors Act Independently of SGLT2 to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice
Justin H. Berger, Timothy R. Matsuura, … Daniel P. Kelly·Circulation ResearchPeer-reviewed·Jul 23, 2024
- Highly selective SGLT2 inhibitors suppress glucose uptake in alpha-TC1 cells, while glucagon secretion is not affected.
Licht Miyamoto, Suguru Nakayama, … Koichiro Tsuchiya·HORMONESPeer-reviewed·Jul 8, 2026
- Vertical sleeve gastrectomy lowers kidney SGLT2 expression in the mouse
E. Akalestou, L. Lopez-Noriega, … G. A. Rutter·bioRxiv·Aug 21, 2019